TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34406354
Drug: Escitalopram (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (up to 20 mg per day for 12 weeks)
Study: 36088373
Drug: Crisis-focused Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisis-focused Cognitive Behavioural Therapy for psychosis (CBTp)
Study: 34389701
Drug: D-fortified yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-fortified yogurt drink (DY; containing 1000 IU vitamin D and 300 mg calcium)
Study: 34086518
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (CON, N=13)
Study: 35796290
Drug: Lactuca Sativa
Normalized name: Lactuca sativa l.
DrugBank: Lactuca sativa whole (DB15604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactuca Sativa syrup (3 times a day for 72 hours)
Study: 33094958
Drug: Tailored therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored therapy
Study: 34910367
Drug: 1% VC-IP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% VC-IP cream
Study: 34701458
Drug: GC4711 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC4711 100 mg IV infusion prior to each SBRT (5×10Gy)
Study: 34701458
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV infusion prior to each SBRT (5×10Gy)
Study: 34528277
Drug: IV administration
Normalized name: IV Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of dexmedetomidine (loading dose 1.75 mcg/kg bwt followed by 1.75 mcg/kg bwt/h) with concurrent target sevoflurane dose reduction of 50%.
Study: 34528277
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (group LPS; seven horses).
Study: 33318079
Drug: Platinum based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum based chemotherapy plus placebo of atezolizumab followed by maintenance niraparib plus placebo of atezolizumab
Study: 32507421
Drug: Plantago major
Normalized name: Plantago major
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantago major syrup
Study: 33993394
Drug: Home management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home management with auto-titrating CPAP (APAP) therapy and telemonitoring
Study: 32171278
Drug: Assertive outreach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive outreach treatment (AOT) plus care as usual (CAU)
Study: 36261145
Drug: nCPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP treatment with nasal mask or prongs
Study: 32854150
Drug: 2 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/kg/d S‐ILE for 6 weeks
Study: 33253259
Drug: tDNA-MI (structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDNA-MI (structured low-calorie meal plan, diabetes-specific meal replacements, exercise prescription, and motivational interviewing)
Study: 33253259
Drug: tDNA-CC (structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDNA-CC (structured low-calorie meal plan, diabetes-specific meal replacements, exercise prescription, and conventional counseling)
Study: 34364702
Drug: Standard pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacologic therapies (Control)
Study: 33084818
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid and cyclosporine‐A (immune modulator therapy)
Study: 36380013
Drug: Sodium-glucose cotransporter-2
Normalized name: glucose / sodium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Study: 39520893
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose
Study: 35377931
Drug: 3% tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% tetracaine plus 0.05% oxymetazoline nasal spray (Kovanaze; KNS)
Study: 34757343
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg (2 hours preoperative)
Study: 33781212
Drug: Guedel Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guedel Oral Airway (GOA)
Study: 34728252
Drug: Final implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final implant restorations assessed by FIPS
Study: 33660080
Drug: Acute alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute alcohol exposure via an aBAC clamp at 80 mg%
Study: 34185197
Drug: mTOR inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR inhibitor everolimus (RADIANT trials)
Study: 32513153
Drug: Treatment from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment from a physical therapist with more knowledge about work-related factors and skills in integrating work participation into care.
Study: 33611699
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of Obstructive Sleep Apnea Syndrome (OSAS)
Study: 35687774
Drug: Infraclavicular brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infraclavicular brachial plexus blockade with hydrodissection (15 mL distilled water + 15 mL 0.5% bupivacaine)
Study: 35687774
Drug: Infraclavicular brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infraclavicular brachial plexus blockade with normal method (30 mL local anesthetic mixture: 15 mL distilled water + 15 mL 0.5% bupivacaine)
Study: 36401445
Drug: Bicarbonated Ringer's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonated Ringer's solution (BRS)
Study: 34138791
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT) with heartbeat-music interventions (recorded maternal lullaby and heartbeat for infants, recorded infant heartbeat and preferred music for mothers)
Study: 32612816
Drug: Therapeutic zinc
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic zinc supplements for diarrhea treatment (20 mg/d for 10 days with each episode; TZ)
Study: 32114513
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with bevacizumab
Study: 36042635
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine treatments (acupuncture including electroacupuncture, moxibustion, manual therapy-type massage)
Study: 36042635
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatments (anti-inflammatory drugs and lifestyle change education)
Study: 36915630
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) therapy
Study: 32578029
Drug: Reminiscence therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy-based care (RTBC)
Study: 33624731
Drug: Control care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control care (CC)
Study: 36284013
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine plus bupivacaine
Study: 35240084
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both tests
Study: 33283766
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg/day) + Amoxicillin (1 g/12 h) + Dexlansoprazole (60 mg/day) for 7 days
Study: 33283766
Drug: Laboratory tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laboratory tests before and after treatment
Study: 34438976
Drug: Subgingival instrumentation
Normalized name: ferric sulfate 21 % Subgingival Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival instrumentation (SI) with local adjunctive use of hyaluronic acid (HA) gel
Study: 34438976
Drug: Adjunctive use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive use of local placebo
Study: 36987929
Drug: warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: warfarin
Study: 34767999
Drug: HDM Sublingual
Normalized name: ODACTRA 12 SQ-HDM Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM Sublingual Immunotherapy (SLIT) for 18 months
Study: 34324016
Drug: Palpation-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation-guided injection
Study: 33687101
Drug: Structural assessment
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structural assessment for medication
Study: 35280426
Drug: Intermittent dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dose apatinib (500 mg/d for 5 days, then 2 days off) plus docetaxel (60 mg/m2 q3w)
Study: 32741788
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional physical therapy only)
Study: 34274622
Drug: Arts therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arts therapies (including story-making, story-telling, drawings, puppetry, songwriting, and empowerment activities)
Study: 32991336
Drug: Self-reported living
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported living with HIV and not on treatment
Study: 36239883
Drug: Trifluridine‐tipiracil monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine‐tipiracil monotherapy
Study: 33245847
Drug: Intravenous belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous belimumab 10 mg/kg every 4 weeks
Study: 34975168
Drug: Herbal remedy
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal remedy for treatment of canine osteoarthritis pain
Study: 32688368
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements (various types) for 12 weeks
Study: 35320494
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard of care and oral Prednisolone in tapered dosage)
Study: 35245946
Drug: Adjunctive membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive membrane sweeping with Foley catheter
Study: 33635238
Drug: Histidine-Tryptophan-Ketoglutarate (HTK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histidine-Tryptophan-Ketoglutarate (HTK) solution
Study: 32591004
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) - loading dose of 1 μg/kg over 10 min followed by continuous infusion of 0.5 μg/kg/h until the end of surgery
Study: 32591004
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline) - equal volume loading dose followed by equal volume continuous infusion until the end of surgery
Study: 32414425
Drug: Baricitinib monotherapy
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib monotherapy
Study: 32521538
Drug: Colonic SCFA
Normalized name: colonial bent grass pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonic SCFA delivery (10 g and 20 g of arabinoxylan oligosaccharides)
Study: 37086257
Drug: Ranibizumab 0.3
Normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.3 mg
Study: 32595137
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention (10 hours/week for 6 months) including medication reviews, prescribing advice, clinical audits, and education.
Study: 32127255
Drug: Active‐Start intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active‐Start intervention (daily before-school physical activity program for 8 weeks)
Study: 35083341
Drug: Probiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic mixture (Ligilactobacillus salivarius LS01 1 × 10^9 live cells and Bifidobacterium breve B632 1 × 10^9 live cells) taken twice daily for eight weeks and then once daily for another eight weeks
Study: 34484368
Drug: Pain during
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain during rectal examination
Study: 34493820
Drug: Molecular-matched treatment
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular-matched treatment
Study: 34493820
Drug: Best investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best investigator's choice (standard therapy)
Study: 35698215
Drug: Anthroposophic supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthroposophic supportive treatment (AST)
Study: 35698215
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anthroposophic base medication)
Study: 32959586
Drug: Ginger-separated moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger-separated moxibustion and Chinese herbal medicine atomization
Study: 36084899
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT), details on dosage and duration not specified
Study: 34643650
Drug: Ustekinumab (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (45 mg or 90 mg at weeks 0 and 4, then at weeks 16 and 28)
Study: 36274662
Drug: Malva Sylvestris
Normalized name: Malva Sylvestris Leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malva Sylvestris cream applied twice a day for up to 14 days
Study: 33646303
Drug: Low-dose decitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose decitabine (15 mg/m2 daily IV for 3 consecutive days) plus recombinant human thrombopoietin (300 U/kg daily)
Study: 34013559
Drug: Solution-focused brief
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution-focused brief therapy (SFBT)
Study: 33531418
Drug: Liraglutide treatment
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide treatment
Study: 33801514
Drug: Disaster prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disaster prevention education with weekly exercise
Study: 35283439
Drug: WeChat messaging
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WeChat messaging with daily individualized guidance
Study: 34519439
Drug: BCAA (2×7
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (2×7 g/day)
Study: 34519439
Drug: Glycine (2×7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine (2×7 g/day)
Study: 35685986
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg intravenously before surgery
Study: 33155849
Drug: Ibuprofen gel
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen gel
Study: 35795713
Drug: BNT162b2 as
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 as second dose (interventional group)
Study: 35795713
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vaccine initially, then BNT162b2 as second dose)
Study: 34316173
Drug: Neurogol syrup
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neurogol syrup (a combination of valerian and lemon balm) with quetiapine, 5 mL every 12 hours for five consecutive days
Study: 34316173
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with quetiapine, 5 mL every 12 hours for five consecutive days
Study: 34316173
Drug: Neurogol syrup
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neurogol syrup (a combination of valerian and lemon balm) with quetiapine
Study: 35451612
Drug: 177Lu-DOTATATE treatment
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-DOTATATE treatment at 7.4 GBq at 10 ± 2-week intervals until a predefined radiation dose to the kidneys was reached.
Study: 35451612
Drug: 177Lu-DOTATATE treatment
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-DOTATATE treatment
Study: 33947374
Drug: Continuing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing the other type of treatment with another therapist
Study: 33947374
Drug: Therapeutic alliance,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic alliance, treatment integrity, and therapist allegiance
Study: 33386040
Drug: PRF adjunct
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRF adjunct (PRF group, PG)
Study: 33386040
Drug: Extraction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction therapy only (spontaneous healing group, SHG)
Study: 35675275
Drug: 15-minutes morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-minutes morning light treatment per day for four weeks
Study: 35675275
Drug: 30-minutes morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minutes morning light treatment per day for four weeks
Study: 35294813
Drug: Iberdomide 0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide 0.30 mg
Study: 33225663
Drug: Intralesional sodium
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intralesional sodium Stibogluconate (1-5 ml depending on lesion size, 100 mg/ml)
Study: 33225663
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of oral Allopurinol (20 mg/kg/day in divided doses) and intralesional sodium Stibogluconate (1-5 ml depending on lesion size, 100 mg/ml)
Study: 34897499
Drug: Abatacept +
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept + MTX ≤8 mg/week
Study: 34897499
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + MTX ≤8 mg/week
Study: 34897499
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + MTX >8 mg/week
Study: 33666187
Drug: Valacyclovir 1000
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1000 mg thrice daily for 7 days
Study: 33666187
Drug: Famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 500 mg thrice daily for 7 days
Study: 32514677
Drug: Core stability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core stability exercises in addition to conventional physical therapy (PT) for 3 months
Study: 32514677
Drug: Core stability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core stability exercises in addition to conventional physical therapy (PT)
Study: 34729862
Drug: Venturi mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venturi mask (VM) therapy
Study: 34749699
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula oxygen therapy (HFNC)
Study: 35234569
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (doubled dosing interval and discontinued etanercept after 6 months)
Study: 35234569
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued standard dose for 6 months and then doubled dosing interval)
Study: 33526504
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy using virtual reality (VR)
Study: 34935687
Drug: Fluid administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administration
Study: 32924553
Drug: Massage Therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage Therapy (MT)
Study: 33731656
Drug: Concurrent Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Exercise (CE)
Study: 32382137
Drug: Escitalopram/memantine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram/memantine combination treatment
Study: 34311755
Drug: Huoxiang Zhengqi
Normalized name: HYPOCHLOROUS ACID 100 mg in 500 mL EXTRACORPOREAL LIQUID [Huoting slight acid hypochlorite disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huoxiang Zhengqi (HXZQ) oral liquid
Study: 32971005
Drug: Durvalumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab monotherapy (1500 mg IV every 4 weeks)
Study: 32971005
Drug: Durvalumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab plus tremelimumab (1500 mg durvalumab + 75 mg tremelimumab IV every 4 weeks for up to four doses, followed by durvalumab maintenance)
Study: 32971005
Drug: Chemotherapy (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (gemcitabine plus cisplatin or gemcitabine plus carboplatin for up to six cycles)
Study: 36470149
Drug: FF/UMEC/VI 100/62.5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/UMEC/VI 100/62.5/25 μg
Study: 33950929
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medicine treatment group
Study: 33082181
Drug: Tablet-delivered educational
Normalized name: tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet-delivered educational videos on physical activity, blood pressure, diet, medications, smoking, and general health (n=220)
Study: 33082181
Drug: Tablet-delivered educational
Normalized name: tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet-delivered educational videos (n=220)
Study: 33944578
Drug: XTJ2 conidial
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XTJ2 conidial suspension (1×10^5 spores/mL)